Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
Identifieur interne : 001305 ( PubMed/Corpus ); précédent : 001304; suivant : 001306Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
Auteurs : J J Ferreira ; O. RascolSource :
- Current opinion in neurology [ 1350-7540 ] ; 2000.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- drug therapy : Movement Disorders, Parkinson Disease.
- prevention & control : Movement Disorders.
- surgery : Movement Disorders.
- therapy : Movement Disorders.
- Humans.
Abstract
Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.
PubMed: 10970061
Links to Exploration step
pubmed:10970061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.</title>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J J" last="Ferreira">J J Ferreira</name>
<affiliation><nlm:affiliation>Clinical Investigation Centre, University Hospital, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10970061</idno>
<idno type="pmid">10970061</idno>
<idno type="wicri:Area/PubMed/Corpus">001305</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001305</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.</title>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J J" last="Ferreira">J J Ferreira</name>
<affiliation><nlm:affiliation>Clinical Investigation Centre, University Hospital, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
</author>
</analytic>
<series><title level="j">Current opinion in neurology</title>
<idno type="ISSN">1350-7540</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (prevention & control)</term>
<term>Movement Disorders (surgery)</term>
<term>Movement Disorders (therapy)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10970061</PMID>
<DateCreated><Year>2000</Year>
<Month>12</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2000</Year>
<Month>12</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1350-7540</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>4</Issue>
<PubDate><Year>2000</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Current opinion in neurology</Title>
<ISOAbbreviation>Curr. Opin. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>431-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreira</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Clinical Investigation Centre, University Hospital, Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Curr Opin Neurol</MedlineTA>
<NlmUniqueID>9319162</NlmUniqueID>
<ISSNLinking>1350-7540</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>49</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>2</Month>
<Day>28</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10970061</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001305 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001305 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:10970061 |texte= Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10970061" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |